These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30652588)

  • 1. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System.
    Naranjo A; Irwin MS; Hogarty MD; Cohn SL; Park JR; London WB
    JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
    Irwin MS; Naranjo A; Zhang FF; Cohn SL; London WB; Gastier-Foster JM; Ramirez NC; Pfau R; Reshmi S; Wagner E; Nuchtern J; Asgharzadeh S; Shimada H; Maris JM; Bagatell R; Park JR; Hogarty MD
    J Clin Oncol; 2021 Oct; 39(29):3229-3241. PubMed ID: 34319759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
    Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
    J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.
    Okamatsu C; London WB; Naranjo A; Hogarty MD; Gastier-Foster JM; Look AT; LaQuaglia M; Maris JM; Cohn SL; Matthay KK; Seeger RC; Saji T; Shimada H
    Pediatr Blood Cancer; 2009 Oct; 53(4):563-9. PubMed ID: 19530234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Shimada H; Umehara S; Monobe Y; Hachitanda Y; Nakagawa A; Goto S; Gerbing RB; Stram DO; Lukens JN; Matthay KK
    Cancer; 2001 Nov; 92(9):2451-61. PubMed ID: 11745303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
    Sokol E; Desai AV; Applebaum MA; Valteau-Couanet D; Park JR; Pearson ADJ; Schleiermacher G; Irwin MS; Hogarty M; Naranjo A; Volchenboum S; Cohn SL; London WB
    J Clin Oncol; 2020 Jun; 38(17):1906-1918. PubMed ID: 32315273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The International Neuroblastoma Pathology Classification (the Shimada system).
    Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B; Stram DO; Gerbing RB; Lukens JN; Matthay KK; Castleberry RP
    Cancer; 1999 Jul; 86(2):364-72. PubMed ID: 10421273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
    Monclair T; Brodeur GM; Ambros PF; Brisse HJ; Cecchetto G; Holmes K; Kaneko M; London WB; Matthay KK; Nuchtern JG; von Schweinitz D; Simon T; Cohn SL; Pearson AD;
    J Clin Oncol; 2009 Jan; 27(2):298-303. PubMed ID: 19047290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project.
    Angelini P; London WB; Cohn SL; Pearson AD; Matthay KK; Monclair T; Ambros PF; Shimada H; Leuschner I; Peuchmaur M; Irwin MS; Baruchel S
    Eur J Cancer; 2012 May; 48(8):1185-91. PubMed ID: 22137163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.
    Umehara S; Nakagawa A; Matthay KK; Lukens JN; Seeger RC; Stram DO; Gerbing RB; Shimada H
    Cancer; 2000 Sep; 89(5):1150-61. PubMed ID: 10964346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG).
    Ohira M; Nakamura Y; Takimoto T; Nakazawa A; Hishiki T; Matsumoto K; Shichino H; Iehara T; Nagase H; Fukushima T; Yoneda A; Tajiri T; Nakagawara A; Kamijo T
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of image-defined risk factors with clinical features, tumor biology, and outcomes in neuroblastoma: a single-center retrospective study.
    Yang DD; Liu C; Gao J; Hu QJ; Liang Y; Liu J
    Eur J Pediatr; 2023 May; 182(5):2189-2196. PubMed ID: 36856889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
    Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB; Cohn SL; Pearson AD; Maris JM
    Br J Cancer; 2009 May; 100(9):1471-82. PubMed ID: 19401703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.
    Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B
    Cancer; 1999 Jul; 86(2):349-63. PubMed ID: 10421272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
    Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
    Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].
    YIN MZ; ZHANG ZD; MA J; SHEN P; CHEN JF; ZHANG HZ
    Zhonghua Bing Li Xue Za Zhi; 2011 Mar; 40(3):151-5. PubMed ID: 21575383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic features of peripheral neuroblastic tumors].
    Yang BF; Fu LB; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroblastoma image-defined risk factors in adrenal neuroblastoma: role of radiologist.
    Lanza C; Galeazzi V; Carboni N; De Berardinis A; De Marino L; Barile A; Giovagnoni A
    Gland Surg; 2019 Sep; 8(Suppl 3):S168-S177. PubMed ID: 31559184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.